AN7973

AN7973 is an benzoxaborole compound, AN7973 blocks intracellular parasite development and inhibits the two Cryptosporidium species (C.parvum and C.hominis) as an Cryptosporidium growth inhibitor[1].

Signaling Pathways >> Anti-infection >> Parasite

Research Areas >> Infection

AN7973 (oral gavage; 5-25 mg/kg; once daily) is efficacious in murine models of both acute and chronic infection by rapidly eliminating C.parvum in vivo[1]. AN7973 (oral gavage; 5 mg/kg, 10 mg/kg, 6.67 mg/kg; once daily, twice daily, three times daily) reduces C.parvum fecal shedding, diarrhea, and dehydration in a neonatal calf model (closely mimics that seen in infants) of cryptosporidiosis[1]. AN7973 possesses favorable safety, stability, and PK parameters as an exciting drug candidate for treating cryptosporidiosis[1]. Animal Model: Four to five weeks NOD scid gamma mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ)(NSG) with chronic Cryptosporidium infection[1] Dosage: 10 mg/kg, 20 mg/kg Administration: Oral gavage; 10 mg/kg, 20 mg/kg; once daily Result: Reduced parasite shedding by >99% at a dose of 25 mg/kg and by >90% at a dose of 10 mg/kg administration. Animal Model: Four-week-old female C57BL/6 IFN-γ−/− mice with acute Cryptosporidium infection[1] Dosage: 5 mg/kg, 10 mg/kg, 25 mg/kg Administration: Oral gavage; 5 mg/kg, 10 mg/kg, 25 mg/kg; once dairy Result: Eliminated C.parvums at a dose-dependent efficacy. Animal Model: One-day-old to two-day-old Holstein bull Neonatal calf model of cryptosporidiosis[1] Dosage: 5 mg/kg, 10 mg/kg, 6.67 mg/kg Administration: Oral gavage; 5 mg/kg, 10 mg/kg, 6.67 mg/kg; once daily, twice daily, three times daily Result: Curtailed parasite shedding and completely eliminated diarrhea.

[1]. 1. Lunde CS, et al. Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis. Nat Commun. 2019 Jun 27; 10(1):2816.